Overview

A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Ed

Status:
Terminated

Trial end date:
2014-10-01

Target enrollment:

Participant gender:

Summary

- To assess the safety of repeated iCo-007 intravitreal injections in treatment of subjects with diabetic macular edema as monotherapy and in combination with ranibizumab or laser photocoagulation - To assess the change in visual acuity and retinal thickness on optical coherence tomography (OCT) from baseline to month 8 and month 12

Phase:

Phase 2

Details

Lead Sponsor:

Johns Hopkins University
Quan Dong Nguyen

Collaborators:

iCo Therapeutics Inc.
Juvenile Diabetes Research Foundation

Treatments:

Ranibizumab